EVFM

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

10-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

— PHEXX® Poised to Become First and Only Hormone-Free Contraceptive Vaginal Gel Approved in UAE — — 2026 Launch Planned for Hormone-Free Contraceptive in UAE — SAN DIEGO, Nov. 21, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or the "Company") (OTCID: EVFM) announced today that the Emirates Drug Establishment (EDE) has issued favorable pricing certificates for PHEXX® (lactic acid, citric acid, potassium bitartrate), which is a preliminary administrative step toward regulatory approval in the United Arab Emirates (UAE). EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovat

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

-- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter -- -- Delivered $1.0 Million of Operating Income in Q3 2025 -- SAN DIEGO, Nov. 13, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and nine-month periods ended September 30, 2025 and provided a business update. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "Sales rebounded in the thi

10-Q - Evofem Biosciences, Inc. (0001618835) (Filer)

DEF 14A - Evofem Biosciences, Inc. (0001618835) (Filer)

PRE 14A - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

-- Evofem Shareholders Did Not Approve the Merger with Aditxt -- -- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales -- SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) ("Evofem" or the "Company"), today announced that at a Special Meeting of Stockholders held this morning, its stockholders did not approve the proposal to adopt the Amended and Restated Merger Agreement dated July 12, 2024, as subsequently amended (the "Merger Agreement"), between the Company, Aditxt, Inc. (NASDAQ:ADTX), and Adifem, Inc., a wholly owned subsidiary of Aditxt, under which Aditxt intended to acquire Evofem. As a result, Evofem has exercised

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

— First ex-U.S. Regulatory Filing for SOLSOEC® — — Pharma 1 Targets 1H 2026 Launch in UAE for SOLOSEC® to Treat Bacterial Vaginosis and Trichomoniasis, leveraging its commercial infrastructure and expertise in women's health — SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem, or the Company) (OTCID: EVFM) announced today that its licensee for the Middle East and North Africa (MENA), private Emirati health care company Pharma 1, has filed an application with the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) seeking approval to commercialize SOLOSEC® (secnidazole) 2 g oral granules, Evofem's FDA-approved single-dose oral t

SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- On World Contraception Day, Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCID: EVFM) honors the millions of people worldwide who rely on contraception not only to prevent pregnancy, but to take control of their health, their futures, and their freedom. Access to contraception remains uneven across countries and communities; the need for more education, innovation, and de-stigmatization has never been greater. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

DEFA14A - Evofem Biosciences, Inc. (0001618835) (Filer)

DEFA14A - Evofem Biosciences, Inc. (0001618835) (Filer)

-- Special Meeting to be held on September 26, 2025 -- SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc. ("Evofem" or the "Company") (OTCID: EVFM) anticipates the approval of the transactions (the "Merger") contemplated by the Amended and Restated Merger Agreement dated as of July 12, 2024, as amended, (collectively, the "Merger Agreement"), with Aditxt, Inc. (NASDAQ:ADTX) and Adifem, Inc., a wholly-owned subsidiary of Aditxt, at the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on September 26, 2025. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.

DEFM14A - Evofem Biosciences, Inc. (0001618835) (Filer)

PREM14A - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

-- Passage of House Bill 3489 allows Illinois pharmacists to prescribe non-hormonal and emergency contraceptives -- -- Ensures a broader range of contraceptive choices is available to women state-wide -- SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- On August 15, 2025, Illinois enacted House Bill 3489, a measure designed to broaden access to contraception for its residents. This legislation permits pharmacists to prescribe a wider array of contraceptive options, including PHEXXI® (lactic acid, citric acid, and potassium bitartrate) , the hormone-free on-demand contraceptive vaginal gel from Evofem Biosciences (OTCID: EVFM). The law is slated to take effect on January 1, 2026.

-- Evofem now holds eleven Orange Book - listed patents covering SOLOSEC into late 2041 -- SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) today announced that a newly-issued U.S. patent which covers SOLOSEC® (secnidazole) 2 g oral granules and one of its labeled indications is now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">